Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhBNP for prevention of contrast-induced nephropathy in CKD patients undergoing elective coronary angiography or PCI
ChiCTR-PPQ-15007599Phase 4Recruiting
- Sponsor
- The Second Hospital of Hebei Medical University
- Start
- Jun 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of nesiritide in contrast-induced nephropathy (CIN) (2 arms), sponsored by The Second Hospital of Hebei Medical University. Primary endpoint: Incidence of contrast-induced nephropathy. Started Jun 2015; status: recruiting.
02
Drugs
nesiritide
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on ChiCTR-PPQ-15007599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-PPQ-15007599.